Download
s41375-020-01102-3.pdf 1,11MB
WeightNameValue
1000 Titel
  • CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
1000 Autor/in
  1. Kaiser, Lisa Marie |
  2. Hunter, Zachary |
  3. Treon, Steven P. |
  4. Buske, Christian |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-12-03
1000 Erschienen in
1000 Quellenangabe
  • 35(2):333-345
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1038/s41375-020-01102-3 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862063/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • It is one of the major aims in cancer research to improve our understanding of the underlying mechanisms which initiate and maintain tumor growth and to translate these findings into novel clinical diagnostic and therapeutic concepts with the ultimate goal to improve patient care. One of the greater success stories in this respect has been Waldenström's Macroglobulinemia (WM), which is an incurable B-cell neoplasm characterized by serum monoclonal immunoglobulin M (IgM) and clonal lymphoplasmacytic cells infiltrating the bone marrow. Recent years have succeeded to describe the molecular landscape of WM in detail, highlighting two recurrently mutated genes, the MYD88 and the CXCR4 genes: MYD88 with an almost constant and recurrent point mutation present in over 90% of patients and CXCR4 with over 40 different mutations in the coding region affecting up to 40% of patients. Intriguingly, both mutations are activating mutations leading in the case of CXCR4 to an indelible activation and perpetual signaling of the chemokine receptor. These data have shed light on the essential role of CXCR4 in this disease and have paved the way to use these findings for predicting treatment response to the Bruton tyrosine kinase (BTK) inhibitor ibrutinib and novel therapeutic approaches in WM, which might be transferable to other related CXCR4 positive diseases. Well known for its central role in cancer progression and distribution, CXCR4 is highlighted in this review with regard to its biology, prognostic and predictive relevance and therapeutic implications in WM.
1000 Sacherschließung
lokal Waldenstrom Macroglobulinemia/pathology [MeSH]
lokal Humans [MeSH]
lokal B-cell lymphoma
lokal Signal Transduction [MeSH]
lokal Review Article
lokal Waldenstrom Macroglobulinemia/metabolism [MeSH]
lokal Animals [MeSH]
lokal Receptors, CXCR4/metabolism [MeSH]
lokal Agammaglobulinaemia Tyrosine Kinase/metabolism [MeSH]
1000 Liste der Beteiligten
  1. https://frl.publisso.de/adhoc/uri/S2Fpc2VyLCBMaXNhIE1hcmll|https://orcid.org/0000-0002-1689-1691|https://frl.publisso.de/adhoc/uri/VHJlb24sIFN0ZXZlbiBQLg==|https://orcid.org/0000-0002-9782-9012
1000 Hinweis
  • DeepGreen-ID: 76223e540d344145b177c08b6df676c7 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. CXCR4 in Waldenström’s Macroglobulinema: chances and challenges
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6471030.rdf
1000 Erstellt am 2023-11-18T10:25:19.338+0100
1000 Erstellt von 322
1000 beschreibt frl:6471030
1000 Zuletzt bearbeitet 2023-12-01T13:32:26.091+0100
1000 Objekt bearb. Fri Dec 01 13:32:26 CET 2023
1000 Vgl. frl:6471030
1000 Oai Id
  1. oai:frl.publisso.de:frl:6471030 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source